Brezosiran

RNA / oligonucleotide

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Huntington's Disease
NCT06585449 · Alnylam Pharmaceuticals
2024-10-14 – 2028-07-05 · Huntington's Disease
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Huntington's Disease: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Brezosiran: this drugPhase 1RNA / oligonucleotideHuntingtin (HTT)not yet gradedNo reviewed efficacy summary in this indication
Valbenazine (Ingrezza)ApprovedSmall moleculevesicular monoamine transporter 2 (VMAT2)Partial signal
NCT04102579: Primary endpoint, change in UHDRS Total Maximal Chorea score (average of weeks 10 and 12): -4.6 with valbenazine vs -1.4 with placebo, treatment effect -3.2 units, p<0.0001 (INGREZZA label, KINECT-HD).
VotoplamPhase 3Small moleculeHuntingtin (HTT)not yet gradedNo reviewed efficacy summary in this indication
TanruprubartPhase 2Monoclonal antibodyComplement C1qnot yet gradedNo reviewed efficacy summary in this indication
Ifezuntirgene InilparvovecPhase 1/2Gene therapy / editingHuntingtin (HTT) genenot yet gradedNo reviewed efficacy summary in this indication
WVE-003Phase 1/2RNA / oligonucleotideHuntingtin (HTT)Weak signal
NCT05032196: Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results).
RG6662
—(overall)
Gene therapy / editing—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Brezosiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
July 2028 (1)
Phase 1Huntington's DiseaseRecruiting
Est. primary completion 2028-07-05 · NCT06585449 · CT.gov ↗
What to watch

See the full readout calendar ↗